Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma  Enter Into Ex-U.S. Licensing Agreement To Commercialize KORSUVA™ Injection In Dialysis Patients With Pruritus; Co To Receive $50M Upfront Cash Payment And $20M Equity Investment